Maite Gorostegui Obanos
Investigador
Research group
Professional network profiles
Last Publications
- Varo A, Castañeda-Heredia A, Chamorro S, Muñoz JP, Gorostegui-Obanos M, Celma MS, Lopez S, Simao M, Pérez-Jaume S and Mora J Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab Frontiers in oncology . 13: 1164949-1164949.
- Mora J, Castañeda-Heredia A, Gorostegui-Obanos M, Varo A, Pérez-Jaume S, Simao M, Muñoz JP, Garraus-Oneca M, Cristina Larrosa Espinosa, Salvador-Marcos N, Lavarino C, Krauel L and Mañe S Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report Cancers . 15(9): .
- Castañeda-Heredia A, Gorostegui-Obanos M, Miralles SL, ALICIA CHAMIZO BREMER, Patiño SC, Flores MA, Garraus-Oneca M, Lazaro JJ, Santa-María López V, Varo A, Muñoz JP and Mora J How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain. ESMO Open . 7(2): 100462-100462.
News
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.